Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch
Tweet Send to a Friend
Citi analyst Samantha Semenkow reiterated a Buy rating and $14.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst comments "Initial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
